Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(20%)

Phase Distribution

Ph phase_1
1
20%
Ph phase_4
1
20%
Ph phase_3
1
20%
Ph phase_2
1
20%

Phase Distribution

1

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
1(25.0%)
Phase 4Post-market surveillance
1(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(2)
Terminated(2)
Other(1)

Detailed Status

Completed2
unknown1
Withdrawn1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
66.7%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (25.0%)
Phase 21 (25.0%)
Phase 31 (25.0%)
Phase 41 (25.0%)

Trials by Status

unknown120%
withdrawn120%
completed240%
terminated120%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_3

A Phase Ⅲa Study of Genetically Modified Recombinant Human Interleukin-11

NCT01663441
unknownphase_2

Comparison of Interleukin-11 and rhTPO for Recurrent Colorectal Cancer Patients With Thrombocytopenia

NCT03823079
withdrawn

Recombinant Human Interleukin-11 Combination Low-dose Rituximab in Immune Thrombocytopenia

NCT01317966
completedphase_4

Effect of rhIL-11 in Patients With Thrombocytopenia for Childhood ALL

NCT02314273
terminatedphase_1

Study Evaluating rhIL-11 in Left-Sided Ulcerative Colitis

NCT00038922

Clinical Trials (5)

Showing 5 of 5 trials
NCT01663441Phase 3

A Phase Ⅲa Study of Genetically Modified Recombinant Human Interleukin-11

Completed
NCT03823079Phase 2

Comparison of Interleukin-11 and rhTPO for Recurrent Colorectal Cancer Patients With Thrombocytopenia

Unknown
NCT01317966

Recombinant Human Interleukin-11 Combination Low-dose Rituximab in Immune Thrombocytopenia

Withdrawn
NCT02314273Phase 4

Effect of rhIL-11 in Patients With Thrombocytopenia for Childhood ALL

Completed
NCT00038922Phase 1

Study Evaluating rhIL-11 in Left-Sided Ulcerative Colitis

Terminated

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5